{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:55:34Z","timestamp":1790769334977,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":52,"publisher":"Springer US","isbn-type":[{"value":"9781071654750","type":"print"},{"value":"9781071654767","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5476-7_4","type":"book-chapter","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:34:13Z","timestamp":1790764453000},"page":"65-81","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of Antisense Gapmers for the Treatment of Huntington\u2019s Disease"],"prefix":"10.1007","author":[{"given":"Tejal","family":"Aslesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"4_CR1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418776932","volume":"11","author":"CD Wurster","year":"2018","unstructured":"Wurster CD, Ludolph AC (2018) Antisense oligonucleotides in neurological disorders. Ther Adv Neurol Disord 11: 1756286418776932. https:\/\/doi.org\/10.1177\/1756286418776932","journal-title":"Ther Adv Neurol Disord"},{"key":"4_CR2","first-page":"83","volume-title":"Handbook of clinical neurology","author":"JPG Vonsattel","year":"2011","unstructured":"Vonsattel JPG, Keller C, Cortes Ramirez EP (2011) Chapter 4 - Huntington\u2019s disease \u2013 neuropathology. In: Weiner WJ, Tolosa E (Eds.) Handbook of clinical neurology. Elsevier, Amsterdam, NL, 83\u2013100"},{"key":"4_CR3","doi-asserted-by":"crossref","unstructured":"Lane RM, Smith A, Baumann T, et al (2018) Translating antisense technology into a treatment for Huntington\u2019s disease. In: Precious SV, Rosser AE, Dunnett SB (eds) Huntington\u2019s disease. Springer, New York, NY, pp 497\u2013523","DOI":"10.1007\/978-1-4939-7825-0_23"},{"key":"4_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.parkreldis.2014.12.013","volume":"21","author":"D Zielonka","year":"2015","unstructured":"Zielonka D, Mielcarek M, Landwehrmeyer GB (2015) Update on Huntington\u2019s disease: advances in care and emerging therapeutic options. Parkinsonism Relat Disord 21:169\u2013178. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.12.013","journal-title":"Parkinsonism Relat Disord"},{"key":"4_CR5","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/mds.26007","volume":"29","author":"EJ Wild","year":"2014","unstructured":"Wild EJ, Tabrizi SJ (2014) Targets for future clinical trials in Huntington\u2019s disease: what\u2019s in the pipeline?. Mov Disord 29:1434\u20131445. https:\/\/doi.org\/10.1002\/mds.26007","journal-title":"Mov Disord"},{"key":"4_CR6","doi-asserted-by":"publisher","first-page":"e107434","DOI":"10.1371\/journal.pone.0107434","volume":"9","author":"NH Skotte","year":"2014","unstructured":"Skotte NH, Southwell AL, \u00d8stergaard ME et al. (2014) Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all huntington disease patients. PLoS One 9:e107434. https:\/\/doi.org\/10.1371\/journal.pone.0107434","journal-title":"PLoS One"},{"key":"4_CR7","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1152\/physrev.00041.2009","volume":"90","author":"C Zuccato","year":"2010","unstructured":"Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease. Physiol Rev 90:905\u2013981. https:\/\/doi.org\/10.1152\/physrev.00041.2009","journal-title":"Physiol Rev"},{"key":"4_CR8","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","volume":"66","author":"Huntington Study Group","year":"2006","unstructured":"Huntington Study Group (2006) Tetrabenazine as antichorea therapy in Huntington disease. Neurology 66:366\u2013372. https:\/\/doi.org\/10.1212\/01.wnl.0000198586.85250.13","journal-title":"Neurology"},{"key":"4_CR9","first-page":"690","volume":"33","author":"T Yero","year":"2008","unstructured":"Yero T, Rey JA (2008) Tetrabenazine (Xenazine), an FDA-approved treatment option for Huntington\u2019s disease\u2013related chorea. Pharm Ther 33:690\u2013694","journal-title":"Pharm Ther"},{"key":"4_CR10","doi-asserted-by":"publisher","first-page":"36040","DOI":"10.52965\/001c.36040","volume":"10","author":"H Gupta","year":"2022","unstructured":"Gupta H, Perkins W, Stark C et al. (2022) Deutetrabenazine for the treatment of chorea associated with Huntington\u2019s disease. Health Psychol Res 10:36040. https:\/\/doi.org\/10.52965\/001c.36040","journal-title":"Health Psychol Res"},{"key":"4_CR11","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1073\/pnas.0501507102","volume":"102","author":"SQ Harper","year":"2005","unstructured":"Harper SQ, Staber PD, He X et al. (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model. Proc Natl Acad Sci 102:5820\u20135825. https:\/\/doi.org\/10.1073\/pnas.0501507102","journal-title":"Proc Natl Acad Sci"},{"key":"4_CR12","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/mt.2008.50","volume":"16","author":"NR Franich","year":"2008","unstructured":"Franich NR, Fitzsimons HL, Fong DM et al. (2008) AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington\u2019s disease. Mol Ther J Am Soc Gene Ther 16:947\u2013956. https:\/\/doi.org\/10.1038\/mt.2008.50","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"4_CR13","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz HB, Stanek LM, Wancewicz EV et al. (2012) Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron 74:1031\u20131044. https:\/\/doi.org\/10.1016\/j.neuron.2012.05.009","journal-title":"Neuron"},{"key":"4_CR14","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","volume":"94","author":"KM Schoch","year":"2017","unstructured":"Schoch KM, Miller TM (2017) Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases. Neuron 94:1056\u20131070. https:\/\/doi.org\/10.1016\/j.neuron.2017.04.010","journal-title":"Neuron"},{"key":"4_CR15","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","volume":"46","author":"X Shen","year":"2018","unstructured":"Shen X, Corey DR (2018) Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res 46:1584\u20131600. https:\/\/doi.org\/10.1093\/nar\/gkx1239","journal-title":"Nucleic Acids Res"},{"key":"4_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/ard.1991.1.11","volume":"1","author":"JM Dagle","year":"1991","unstructured":"Dagle JM, Weeks DL, Walder JA (1991) Pathways of degradation and mechanism of action of antisense oligonucleotides in Xenopus laevis embryos. Antisense Res Dev 1:11\u201320. https:\/\/doi.org\/10.1089\/ard.1991.1.11","journal-title":"Antisense Res Dev"},{"key":"4_CR17","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1093\/nar\/gkw236","volume":"44","author":"RL Juliano","year":"2016","unstructured":"Juliano RL (2016) The delivery of therapeutic oligonucleotides. Nucleic Acids Res 44:6518\u20136548. https:\/\/doi.org\/10.1093\/nar\/gkw236","journal-title":"Nucleic Acids Res"},{"key":"4_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","volume":"14","author":"C Rinaldi","year":"2018","unstructured":"Rinaldi C, Wood MJA (2018) Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 14:9\u201321. https:\/\/doi.org\/10.1038\/nrneurol.2017.148","journal-title":"Nat Rev Neurol"},{"key":"4_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","volume":"57","author":"CF Bennett","year":"2017","unstructured":"Bennett CF, Baker BF, Pham N et al. (2017) Pharmacology of antisense drugs. Annu Rev Pharmacol Toxicol 57:81\u2013105. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010716-104846","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"4_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3390\/molecules22040563","volume":"22","author":"V Sardone","year":"2017","unstructured":"Sardone V, Zhou H, Muntoni F et al. (2017) Antisense oligonucleotide-based therapy for neuromuscular disease. Molecules 22:563. https:\/\/doi.org\/10.3390\/molecules22040563","journal-title":"Molecules"},{"key":"4_CR21","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.1021\/ja00718a039","volume":"92","author":"F Eckstein","year":"1970","unstructured":"Eckstein F (1970) Nucleoside phosphorothioates. J Am Chem Soc 92:4718\u20134723. https:\/\/doi.org\/10.1021\/ja00718a039","journal-title":"J Am Chem Soc"},{"key":"4_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1073\/pnas.75.1.285","volume":"75","author":"ML Stephenson","year":"1978","unstructured":"Stephenson ML, Zamecnik PC (1978) Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A 75:285\u2013288. https:\/\/doi.org\/10.1073\/pnas.75.1.285","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4_CR23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/s0092-8674(00)81369-0","volume":"87","author":"L Mangiarini","year":"1996","unstructured":"Mangiarini L, Sathasivam K, Seller M et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493\u2013506. https:\/\/doi.org\/10.1016\/s0092-8674(00)81369-0","journal-title":"Cell"},{"key":"4_CR24","doi-asserted-by":"publisher","first-page":"9634","DOI":"10.1093\/nar\/gkt725","volume":"41","author":"ME \u00d8stergaard","year":"2013","unstructured":"\u00d8stergaard ME, Southwell AL, Kordasiewicz H et al. (2013) Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res 41:9634\u20139650. https:\/\/doi.org\/10.1093\/nar\/gkt725","journal-title":"Nucleic Acids Res"},{"key":"4_CR25","doi-asserted-by":"publisher","first-page":"eaar3959","DOI":"10.1126\/scitranslmed.aar3959","volume":"10","author":"AL Southwell","year":"2018","unstructured":"Southwell AL, Kordasiewicz HB, Langbehn D et al. (2018) Huntingtin suppression restores cognitive function in a mouse model of Huntington\u2019s disease. Sci Transl Med 10:eaar3959. https:\/\/doi.org\/10.1126\/scitranslmed.aar3959","journal-title":"Sci Transl Med"},{"key":"4_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","volume":"101","author":"A Yamamoto","year":"2000","unstructured":"Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease. Cell 101:57\u201366. https:\/\/doi.org\/10.1016\/S0092-8674(00)80623-6","journal-title":"Cell"},{"key":"4_CR27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/ejhg.2010.229","volume":"19","author":"SC Warby","year":"2011","unstructured":"Warby SC, Visscher H, Collins JA et al. (2011) HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. Eur J Hum Genet 19:561\u2013566. https:\/\/doi.org\/10.1038\/ejhg.2010.229","journal-title":"Eur J Hum Genet"},{"key":"4_CR28","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","volume":"19","author":"EL Pfister","year":"2009","unstructured":"Pfister EL, Kennington L, Straubhaar J et al. (2009) Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington\u2019s disease patients. Curr Biol 19:774\u2013778. https:\/\/doi.org\/10.1016\/j.cub.2009.03.030","journal-title":"Curr Biol"},{"key":"4_CR29","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/mt.2015.128","volume":"23","author":"C Kay","year":"2015","unstructured":"Kay C, Collins JA, Skotte NH et al. (2015) Huntingtin haplotypes provide prioritized target panels for allele-specific silencing in Huntington's disease patients of European ancestry. Mol Ther 23:1759\u20131771. https:\/\/doi.org\/10.1038\/mt.2015.128","journal-title":"Mol Ther"},{"key":"4_CR30","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/ejhg.2016.169","volume":"25","author":"C Kay","year":"2017","unstructured":"Kay C, Tirado-Hurtado I, Cornejo-Olivas M et al. (2017) The targetable A1 Huntington's disease haplotype has distinct Amerindian and European origins in Latin America. Eur J Hum Genet 25:332\u2013340. https:\/\/doi.org\/10.1038\/ejhg.2016.169","journal-title":"Eur J Hum Genet"},{"key":"4_CR31","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/ejhg.2013.2","volume":"21","author":"FK Baine","year":"2013","unstructured":"Baine FK, Kay C, Ketelaar ME et al. (2013) Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes. Eur J Hum Genet 21:1120\u20131127. https:\/\/doi.org\/10.1038\/ejhg.2013.2","journal-title":"Eur J Hum Genet"},{"key":"4_CR32","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ajhg.2009.02.003","volume":"84","author":"SC Warby","year":"2009","unstructured":"Warby SC, Montpetit A, Hayden AR et al. (2009) CAG expansion in the Huntington's disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet 84:351\u2013366. https:\/\/doi.org\/10.1016\/j.ajhg.2009.02.003","journal-title":"Am J Hum Genet"},{"key":"4_CR33","unstructured":"Achey MA. Meet the compounds: WVE-120101 and WVE-120102. In: Huntington Study group. https:\/\/huntingtonstudygroup.org\/hd-insights\/meet-the-compounds-wve-120101-and-wve-120102\/. Accessed 24 Oct 2025"},{"key":"4_CR34","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nbt.3948","volume":"35","author":"N Iwamoto","year":"2017","unstructured":"Iwamoto N, Butler DCD, Svrzikapa N et al. (2017) Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nat Biotechnol 35:845\u2013851. https:\/\/doi.org\/10.1038\/nbt.3948","journal-title":"Nat Biotechnol"},{"key":"4_CR35","doi-asserted-by":"publisher","first-page":"102246","DOI":"10.1016\/j.omtn.2024.102246","volume":"35","author":"N Iwamoto","year":"2024","unstructured":"Iwamoto N, Liu Y, Frank-Kamenetsky M et al. (2024) Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant HTT. Mol Ther Nucleic Acids 35:102246. https:\/\/doi.org\/10.1016\/j.omtn.2024.102246","journal-title":"Mol Ther Nucleic Acids"},{"key":"4_CR36","unstructured":"Huntington\u2019s Disease Society of America (2016) WAVE life sciences receives orphan drug designation from FDA for its lead candidate designed to treat Huntington\u2019s disease. https:\/\/hdsa.org\/news\/wave-life-sciences-receives-orphan-drug-designation-from-fda-for-its-lead-candidate-designed-to-treat-huntingtons-disease\/. Accessed 24 Oct 2025"},{"key":"4_CR37","unstructured":"Inc WLSU (2024) Wave life sciences announces positive results from phase 1b\/2a SELECT-HD trial with first clinical demonstration of allele-selective mutant huntingtin lowering in Huntington\u2019s disease. In: GlobeNewswire News Room. https:\/\/www.globenewswire.com\/news-release\/2024\/06\/25\/2903685\/0\/en\/Wave-Life-Sciences-Announces-Positive-Results-from-Phase-1b-2a-SELECT-HD-Trial-with-First-Clinical-Demonstration-of-Allele-Selective-Mutant-Huntingtin-Lowering-in-Huntington-s-Dise.html. Accessed 24 Oct 2025"},{"key":"4_CR38","unstructured":"Chrismatranga\u2002(2024)\u2002Vico\u2002therapeutics announces positive interim phase 1\/2a clinical data of VO659 in treatment of Huntington\u2019s disease. In: Vico Ther. https:\/\/vicotx.com\/press-release\/vico-therapeutics-announces-positive-interim-phase-1-2a-clinical-data-of-vo659-in-treatment-of-huntingtons-disease\/. Accessed 24Oct 2025"},{"key":"4_CR39","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.cell.2019.06.036","volume":"178","author":"J-M Lee","year":"2019","unstructured":"Lee J-M, Correia K, Loupe J et al. (2019) CAG repeat not polyglutamine length determines timing of Huntington\u2019s disease onset. Cell 178:887\u2013900.e14. https:\/\/doi.org\/10.1016\/j.cell.2019.06.036","journal-title":"Cell"},{"key":"4_CR40","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S1474-4422(17)30161-8","volume":"16","author":"DJH Moss","year":"2017","unstructured":"Moss DJH, Pardi\u00f1as AF, Langbehn D et al. (2017) Identification of genetic variants associated with Huntington\u2019s disease progression: a genome-wide association study. Lancet Neurol 16:701\u2013711. https:\/\/doi.org\/10.1016\/S1474-4422(17)30161-8","journal-title":"Lancet Neurol"},{"key":"4_CR41","doi-asserted-by":"publisher","first-page":"eadn4600","DOI":"10.1126\/scitranslmed.adn4600","volume":"17","author":"EL Bunting","year":"2025","unstructured":"Bunting EL, Donaldson J, Cumming SA et al. (2025) Antisense oligonucleotide-mediated MSH3 suppression reduces somatic CAG repeat expansion in Huntington\u2019s disease iPSC-derived striatal neurons. Sci Transl Med 17:eadn4600. https:\/\/doi.org\/10.1126\/scitranslmed.adn4600","journal-title":"Sci Transl Med"},{"key":"4_CR42","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3233\/JHD-189003","volume":"7","author":"FB Rodrigues","year":"2018","unstructured":"Rodrigues FB, Wild EJ (2018) Huntington\u2019s disease clinical trials corner. J Huntingt Dis 7:279\u2013286. https:\/\/doi.org\/10.3233\/JHD-189003","journal-title":"J Huntingt Dis"},{"key":"4_CR43","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3233\/JHD-239001","volume":"12","author":"C Estevez-Fraga","year":"2023","unstructured":"Estevez-Fraga C, Tabrizi SJ, Wild EJ (2023) Huntington\u2019s disease clinical trials corner. J Huntingt Dis 12:169\u2013185. https:\/\/doi.org\/10.3233\/JHD-239001","journal-title":"J Huntingt Dis"},{"key":"4_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JHD-240017","volume":"13","author":"C Estevez-Fraga","year":"2024","unstructured":"Estevez-Fraga C, Tabrizi SJ, Wild EJ (2024) Huntington\u2019s disease clinical trials corner: March 2024. J Huntingt Dis 13:1\u201314. https:\/\/doi.org\/10.3233\/JHD-240017","journal-title":"J Huntingt Dis"},{"key":"4_CR45","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Leavitt BR, Landwehrmeyer GB et al. (2019) Targeting huntingtin expression in patients with Huntington\u2019s disease. N Engl J Med 380:2307\u20132316. https:\/\/doi.org\/10.1056\/NEJMoa1900907","journal-title":"N Engl J Med"},{"key":"4_CR46","unstructured":"CHDI (2022) Understanding the treatment and post-treatment effects of tominersen in the Phase III GENERATION HD1 study. https:\/\/medically.gene.com\/global\/en\/unrestricted\/neuroscience\/CHDI-2022\/chdi-2022-presentation-lauren-understanding-the-treatme.html. Accessed 27 Oct 2025"},{"key":"4_CR47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett CF, Swayze EE (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50:259\u2013293. https:\/\/doi.org\/10.1146\/annurev.pharmtox.010909.105654","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"4_CR48","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1124\/dmd.106.012401","volume":"35","author":"RZ Yu","year":"2007","unstructured":"Yu RZ, Kim T-W, Hong A et al. (2007) Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 35:460\u2013468. https:\/\/doi.org\/10.1124\/dmd.106.012401","journal-title":"Drug Metab Dispos"},{"key":"4_CR49","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","volume":"37","author":"W Shen","year":"2019","unstructured":"Shen W, De Hoyos CL, Migawa MT et al. (2019) Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat Biotechnol 37:640\u2013650. https:\/\/doi.org\/10.1038\/s41587-019-0106-2","journal-title":"Nat Biotechnol"},{"key":"4_CR50","unstructured":"Meglio M (2025) Gene therapy AMT-130 meets end points in Huntington study; FDA submission to follow | NeurologyLive - Clinical Neurology News and Neurology Expert Insights.\u2002https:\/\/www.neurologylive.com\/view\/gene-therapy-amt-130-meets-endpoints-huntington-study-fda-submission-follow. Accessed 24 Oct 2025"},{"key":"4_CR51","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1016\/j.ymthe.2025.04.038","volume":"33","author":"L Torres-Masjoan","year":"2025","unstructured":"Torres-Masjoan L, Aguti S, Zhou H, Muntoni F (2025) Clinical applications of exon skipping antisense oligonucleotides in neuromuscular diseases. Mol Ther 33:2689\u20132704. https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.038","journal-title":"Mol Ther"},{"key":"4_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/978-1-4939-8651-4_4","volume":"1828","author":"K Goodkey","year":"2018","unstructured":"Goodkey K, Aslesh T, Maruyama R, Yokota T (2018) Nusinersen in the treatment of spinal muscular atrophy. Meth Mol Biol Clifton NJ 1828:69\u201376. https:\/\/doi.org\/10.1007\/978-1-4939-8651-4_4","journal-title":"Meth Mol Biol Clifton NJ"}],"container-title":["Methods in Molecular Biology","Gapmers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5476-7_4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:02:38Z","timestamp":1790766158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5476-7_4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071654750","9781071654767"],"references-count":52,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5476-7_4","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}